Danielle Brill
Stock Analyst at Truist Securities
(3.66)
# 780
Out of 5,123 analysts
97
Total ratings
43.68%
Success rate
9.8%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $23.54 | +61.43% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $22.86 | +162.47% | 3 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $172 → $169 | $137.93 | +22.53% | 8 | Jan 8, 2026 | |
| IMVT Immunovant | Maintains: Hold | $16 → $22 | $24.06 | -8.56% | 6 | Jan 8, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $48 → $45 | $36.41 | +23.59% | 9 | Jan 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $56 → $63 | $46.56 | +35.31% | 2 | Jan 8, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $80 → $86 | $63.73 | +34.94% | 3 | Jan 8, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $535 → $530 | $331.24 | +60.00% | 3 | Jan 8, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $105 → $190 | $76.43 | +148.59% | 4 | Dec 16, 2025 | |
| IRON Disc Medicine | Maintains: Buy | $86 → $114 | $78.33 | +45.54% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $26.00 | +80.77% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $458.81 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $21.02 | +14.20% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $24.52 | +112.07% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $20.02 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $57.15 | +38.23% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $10.26 | +75.44% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $17.03 | +780.80% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $185.36 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $820.31 | -26.25% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $23.46 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $40.39 | +23.79% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $26.57 | +91.95% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $9.11 | +997.69% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $72.36 | - | 9 | Sep 18, 2023 |
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $23.54
Upside: +61.43%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $22.86
Upside: +162.47%
Neurocrine Biosciences
Jan 8, 2026
Maintains: Buy
Price Target: $172 → $169
Current: $137.93
Upside: +22.53%
Immunovant
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $24.06
Upside: -8.56%
Harmony Biosciences Holdings
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $36.41
Upside: +23.59%
Dianthus Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $56 → $63
Current: $46.56
Upside: +35.31%
BridgeBio Pharma
Jan 8, 2026
Maintains: Buy
Price Target: $80 → $86
Current: $63.73
Upside: +34.94%
Alnylam Pharmaceuticals
Jan 8, 2026
Maintains: Buy
Price Target: $535 → $530
Current: $331.24
Upside: +60.00%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $76.43
Upside: +148.59%
Disc Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $78.33
Upside: +45.54%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $26.00
Upside: +80.77%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $458.81
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $21.02
Upside: +14.20%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $24.52
Upside: +112.07%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $20.02
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $57.15
Upside: +38.23%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $10.26
Upside: +75.44%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $17.03
Upside: +780.80%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $185.36
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $820.31
Upside: -26.25%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $23.46
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $40.39
Upside: +23.79%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $26.57
Upside: +91.95%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $9.11
Upside: +997.69%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $72.36
Upside: -